Tarsons Products Limited — Investor Meet, 11-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Tarsons Products reported Q3 FY26 consolidated revenue of INR 108 Cr (+12.8% YoY) and adjusted PAT of INR 6.4 Cr (+21.4% YoY). Nine-month EBITDA margin improved to 32.9% (+190 bps YoY).

Management highlights strong industry tailwinds, especially in biopharma. New Panchla facilities are commercializing; bioprocess products are selling, with cell culture capex coming in Q4. Expect stronger revenue growth from FY27 as new products scale, navigating aggressive domestic pricing. New trade agreements with EU & US offer tailwinds for global growth. Nerbe's sales saw marginal growth, aided by Euro depreciation. Management remains confident in Tarsons' long-term market leadership despite competitive dynamics.